ROIV Roivant Sciences Ltd. Insider Trading

Director Keith S Manchester sold 1,638,163 shares (1.64M) for $56,444,075.76 in 6 transactions over 4 days, reducing holdings 48.4%.

Keith S Manchester, a Director at Roivant Sciences, executed 6 separate sales totaling 1,638,163 shares for $56,444,075.76 between June 26–30, 2026, reducing his shareholding from 3,386,566 shares to 1,748,403 shares (-48.4%). The sales occurred at an average price of $34.46, near the current price of $35.39, while the stock has appreciated 18.0% over the prior 30 days and 27.1% over the prior 90 days. Notably, his prior 5 sales at this ticker showed positive 90-day returns (ranging 9.2%–11.4%), meaning none were well-timed by the metric that sells preceded declines—all occurred before subsequent gains. The underlying company generated only $1,999,000.00 in quarterly revenue, reported a net loss of $-265,891,000.00, and experienced a -71.6% year-over-year revenue decline, raising questions about cash burn and runway alongside recent stock momentum.

Director Daniel Allen Gold sold 1,438,163 shares for $49.4M across 5 trades (June 26–30) at $33.92–$35.28, reducing stake 9.5%

Daniel Allen Gold, as Director of Roivant Sciences, executed 5 separate sales totaling 1,438,163 shares for $49,354,075.76 at blended average price $34.32 during June 26–30, reducing his post-transaction holdings to 13,689,166 shares (9.5% reduction vs pre-transaction 15,127,329 shares). The sales occurred as ROIV is -1.4% from its 52-week high of $35.90 and has appreciated 18.0% over 30 days and 27.1% over 90 days. Notably, Gold's prior 5 trades at ROIV (all sells in February 2026) produced positive 90-day returns of 4.9%–5.9%, meaning the stock rose after each prior sale at this ticker; a 0% well-timed rate over those 5 prior ROIV trades indicates none preceded subsequent declines. Contemporaneously, the company reported trailing-quarter revenue of $1,999,000.00 and full-year net income of -$265,891,000.00 with annual revenue decline of -71.6%, while retaining a $25.5B market cap. The scale of this 1.44M-share liquidation against the backdrop of sustained unprofitability and collapsing revenue—combined with the absence of well-timed prior sell patterns at this ticker—warrants investor attention to whether the sale reflects market window management or operational headwinds below the surface.

QVT Financial LP sold 1,438,163 shares of ROIV for $49.4M across 5 transactions (June 26-30), reducing stake by 9.5% to 13.69M shares.

QVT Financial LP executed 5 separate sales totaling 1,438,163 shares for $49,354,075.76 at an average price of $34.32 between June 26–30, 2026. This represents a 9.5% reduction in holdings from 15,127,329 shares to 13,689,166 shares. The sale occurred near the 52-week high of $35.90 (current price $35.39 is -1.4% from that peak), amid strong recent momentum (+18.0% over 30 days, +27.1% over 90 days). However, at the same ticker (ROIV), QVT's prior 5 sell transactions all resulted in subsequent stock appreciation: 30-day returns of +4.9% to +5.9%, and 90-day returns of +9.2% to +11.4%. None of those 5 prior sells at ROIV were well-timed (0 of 5 showed negative 90-day returns). Separately, across all holdings cross-ticker, QVT's 20 prior sells averaged +15.3% 90-day return with a 0.00% well-timed rate, indicating a pattern of selling before rallies rather than declines. The company's fundamentals remain challenged: revenue was $2.0M in the latest quarter (annual growth -71.6%) and net income was $-265.9M, with an unprofitable full fiscal year.

Mayukh Sukhatme (President & CIO) sells 1.00M shares for $34.1M across 2 transactions at ROIV, retaining 18.68M shares plus substantial option holdings

Mayukh Sukhatme executed 2 separate sales totaling 1,000,000 shares for $34,105,000.00 at blended average price $34.10, reducing his non-derivative holdings by 5.1% to 18.68M shares. The stock currently trades at $34.73, near its 52-week high of $34.83 (-0.3% from the 52-week high), and has risen 15.8% over the past 30 days and 25.4% over the past 90 days. Sukhatme retains 28,948,726 shares in derivative form (stock options), meaning his overall economic position remains substantial. At this ticker, his prior 5 sales show mixed post-transaction performance: only 1 of 5 were well-timed at the 90-day mark, with returns ranging from -13.1% to +27.6%. The company reported quarterly revenue of $1,999,000.00 and net income of $-265,891,000.00, with annual revenue declining 71.6% year-over-year, providing context for evaluating whether this partial reduction signals broader concerns.

Roivant CEO Eric Venker sells 200,000 shares for $6.6M on scheduled 10b5-1 plan; retains 1,613,063 shares plus 4,244,834 stock options

Eric Venker, President & Immunovant CEO, executed 2 separate sales totaling 200,000 shares for $6,631,267.64 at a blended average price of $33.16 on 2026-06-24 as part of a pre-arranged 10b5-1 trading plan. His non-derivative holdings post-transaction stand at 1,613,063 shares, representing an 11.0% reduction from pre-transaction levels, though his derivative holdings of 4,244,834 stock options remain intact. Roivant's fundamentals remain challenged, with net income of $-265,891,000.00 in the latest fiscal year and annual revenue growth of -71.6%, yet the stock has appreciated 15.2% over the past 30 days and 28.5% over 90 days—substantially outperforming his historical cross-ticker average 90-day return of 31.8% after sells. The scheduled nature of this trade via 10b5-1 plan removes discretionary timing as a signal factor.

ROIV President Eric Venker sells 200,000 shares at $30.27; scheduled 10b5-1 plan. Holds 1.61M post-sale.

Eric Venker, President & Immunovant CEO, sold 200,000 shares at $30.27 on 2026-05-22 as part of a pre-arranged 10b5-1 trading plan. This is a scheduled, non-discretionary transaction. His holding dropped from 1.81M to 1.61M shares (-11.0% vs pre-transaction holdings). The company is unprofitable with annual revenue growth of -71.6%, though the stock trades within its 52-week range at $29.96 current price. Prior same-ticker sales at ROIV show mixed 30/90-day post-sale price performance (ranging from +0.2% to +22.3% over 30 days), and cross-ticker selling history averaged 90-day returns of +31.3%. The scheduled nature of this transaction limits inference about insider sentiment; it reflects pre-planned execution rather than discretionary decision-making.

Venker Eric (then-CEO of Immunovant) sold 200,000 shares of ROIV at $29.59 under 10b5-1 plan

Eric Venker, who was President & Immunovant CEO at the time of filing, sold 200,000 shares for $5,918,000.00 on 2026-04-20 pursuant to a pre-arranged 10b5-1 trading plan, reducing his holdings from 1,847,546 shares to 1,647,546 shares (a 10.8% reduction in position). As a scheduled transaction executed under a Rule 10b5-1 plan rather than a discretionary choice, this sale does not reflect timing-based decision-making by the insider. The transaction represents a moderate portfolio adjustment and warrants standard monitoring as part of tracking insider holdings changes, though the pre-arranged nature limits what can be inferred about insider sentiment regarding near-term stock performance.

CEO Gline Matthew sells 289.8K shares at $29.16; holds 16.74M post-sale amid -76.7% annual revenue decline.

CEO Gline Matthew sold 289,774 shares of ROIV at $29.16, reducing his holdings by 1.7% to 16.74M shares. The sale occurred near the 52-week high (stock currently at $29.08, within 2.5% of the $29.83 peak), and ROIV has gained 26.5% over 90 days. However, the fundamental picture is deteriorating sharply: Roivant's annual revenue contracted 76.7% year-over-year to just $2.0M in the latest quarter, and the company posted a $-265.9M net loss over its most recent full fiscal year. At the same ticker, the CEO's prior 2 sales (December 2025) each showed positive 90-day returns of +29.4%, and his cross-ticker sell history has a 25% well-timed rate (meaning 75% of his prior sales were poorly timed, followed by further stock gains). This sale occurs against a backdrop of severe top-line contraction and deep unprofitability, creating a potential divergence between recent price momentum and operating fundamentals that warrants investor scrutiny of the company's path to profitability.

Director Meghan Fitzgerald sells 70.0K shares at $27.45 for $1.9M, reducing holdings 62.0%

Director Meghan Fitzgerald sold 70,000 shares at $27.45 on 2026-03-26, reducing her position from 112,963 shares to 42,963 shares—a 62.0% reduction in holdings. The sale occurred near the 52-week high of $29.72, just 11.1% below peak, and at a 4.0% premium to the current price of $26.41. However, context is troubling: Roivant Sciences reported quarterly revenue of $2.0M against a net loss of $265.9M, with annual revenue declining 76.7% year-over-year, and the company remains unprofitable. Across her cross-ticker trading history, Fitzgerald's prior sells showed a 0.00% well-timed rate—meaning her previous exit points were followed by positive returns, indicating she sold before gains materialized. The substantial reduction in exposure during a period of severe operational deterioration and against a backdrop of poorly-timed historical sells warrants investor scrutiny.

Venker, then-President & CEO of Immunovant, sold 200,000 shares of ROIV at $28.24 via 10b5-1 plan

Venker Eric, who was President & CEO of Immunovant at the time of this transaction, sold 200,000 shares on 2026-03-17 at $28.24 as part of a pre-arranged 10b5-1 trading plan, resulting in a $5.6M proceeds and reducing his holdings from 1.85M shares to 1.65M shares. Because this sale was scheduled under a 10b5-1 plan rather than discretionary, it does not reflect a contemporaneous investment decision or timing choice. The -10.8% reduction in his holdings occurs within the framework of a predetermined trading schedule, which limits the inferential weight an investor should place on the transaction as a signal of conviction or concern about the stock's prospects.